Lexaria Bioscience Corp. (Nasdaq: LEXX) announced on March 26, 2026, the granting of five new patents, further expanding its intellectual property portfolio. The patents cover innovations in three key therapeutic areas: hypertension, epilepsy, and diabetes. Notably, two of the new patents are specifically for diabetes treatment utilizing Lexaria’s proprietary DehydraTECH technology in combination with GLP-1 drugs, a significant development given the intense global competition in the GLP-1 market.
In patent Family #21, which addresses compositions and methods for treating hypertension, Lexaria received two new patents in Japan (Nos. 7823051 and 7823052), both issued on February 20, 2026, with terms extending to April 25, 2043. This adds to the company’s existing three U.S. and one European granted patents in this family. The expansion into Japan underscores Lexaria's strategic focus on securing intellectual property in major global markets.
For patent Family #24, focused on epilepsy treatments, Lexaria was granted one new Australian patent (No. 2024205127), issued on February 12, 2026, with a term ending on February 20, 2044. This complements the company’s existing six U.S., one European Union, and four previous Australian patents in this family, reinforcing its position in the epilepsy treatment space.
The most notable additions are in patent Family #27, which covers compositions and methods for treating diabetes. Lexaria received two new Australian patents (Nos. 2025205229 and 2024394427), both issued on February 12, 2026, with terms ending on December 3, 2044. These patents are particularly significant as they relate to the use of Lexaria’s DehydraTECH technology with GLP-1 drugs, a class of medications widely used for diabetes management. The company's recent Phase 1b Human Study (GLP-1-H24-4) conducted in Australia demonstrated the capabilities of DehydraTECH in combination with GLP-1 drugs, providing support for these patent awards.
Lexaria CEO Richard Christopher emphasized the importance of these patents, stating, "Given the international race within the GLP-1 industry, our new patents related to diabetes treatments utilizing our proprietary technology in conjunction with already-approved GLP-1 drugs is a notable achievement." The company’s ongoing R&D projects are dedicated to advancing commercial relationships and establishing valuable IP across jurisdictions. Lexaria expects to receive additional patent awards in the future and will continue to report on them.
Lexaria’s DehydraTECH platform is a patented drug delivery formulation technology that improves oral drug absorption, reduces side effects, and enhances blood-brain barrier crossing. The company holds a robust portfolio with 65 patents granted and additional patents pending worldwide. More information is available at www.lexariabioscience.com.
